文献速递免疫规划

狂犬病病毒糖蛋白血清学ELISA用于测量疫苗接种者中和抗体

Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
PubMed 文献 · Vaccine · 2019-08-27

本研究开发并验证了一种基于重组狂犬病病毒糖蛋白的血清学ELISA试剂盒,用于半定量测量疫苗接种者血清中的中和抗体滴度。该方法以HRIG参考品检测,检出限为0.02-0.06 IU/mL,线性范围0.2-10.0 IU/mL,诊断特异性100%、敏感性91.1%。该ELISA可作为评估疫苗接种状态的实用工具。

要点

  • ELISA以重组RABV GP为捕获抗原,血清稀释1:20,包被浓度1 µg/mL。
  • HRIG参考品下检出限0.02-0.06 IU/mL,线性范围0.2-10.0 IU/mL。
  • 以1.5 IU/mL为cut-off,诊断特异性100%、敏感性91.1%。

核心结论

  • 该ELISA适用于半定量测量人血清中和抗体滴度以评估疫苗接种状态。
  • 该方法简便、快速、低成本、高通量,适合监测疫苗接种后免疫反应。

研究设计与样本

  • 使用哺乳动物细胞表达的重组RABV GP作为捕获抗原建立ELISA方法。
  • 先后以HuMAb NM57和HRIG参考品进行方法建立与验证。
  • 检测了12份已知阴性人血清和415份未知阳性人血清,后者用RFFIT和ELISA双盲测试。

主要发现

  • ELISA板包被RABV GP浓度为1 µg/mL,人血清样本最佳稀释度为1:20。
  • 使用HRIG参考品时,检出限为0.02-0.06 IU/mL,线性范围为0.2-10.0 IU/mL。
  • 批间变异系数(CV)为6.60-10.79%,表明重现性良好。
  • 12份已知阴性人血清经ELISA检测均未出现阳性,显示特异性。
  • 以1.5 IU/mL为cut-off值时,诊断特异性为100%,敏感性为91.1%。

关键数值与推荐

  • 血清中和抗体滴度≥0.5 IU/mL提示对疫苗接种有充分应答。
  • ELISA的VNA滴度cut-off值设为1.5 IU/mL以确保无假阳性。
  • 诊断特异性100%,敏感性91.1%。

临床怎么用

  • 该ELISA试剂盒可用于疫苗接种后人群的免疫状态监测。
  • 其简便、快速、低成本、高通量的特点适合大规模筛查。
  • 结果判读时以1.5 IU/mL为cut-off值,高于此值判为阳性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination provides protection against infection by inducing VNAs mainly against RABV surface GP. The measurement of VNAs to RABV is commonly used to assess the level of immunity in humans and animals after vaccination. A VNA titer of ≥ 0.5 IU/mL of sera indicates adequate response to vaccination. Here, we report the development and validation of a RABV GP serology ELISA kit for semi-quantitative measurement of VNA titers in sera of vaccinated human subjects. METHODS: Using a recombinant RABV GP expressed in mammalian cells as the capture antigen, the ELISA method was established using HuMAb NM57 reference initially and HRIG reference subsequently. The limit of detection (LOD), linear range, reproducibility, and precision of the method were examined. Specificity and sensitivity were established to assess the diagnostic accuracy. RESULTS: RABV GP for ELISA plate coating and optimal dilution of human serum sample was 1 µg/mL and 1:20, respectively. Multiple assays were carried out by different technicians at different laboratories for assay standardization. Using the HRIG reference, the LOD was found to be 0.02-0.06 IU/mL and the linear range was 0.2-10.0 IU/ mL. The inter-assay CVs were in the range of 6.60-10.79%, indicating the reproducibility. None of the 12 known negative human sera, tested positive by ELISA, highlighting the specificity. A total of 415 unknown positive human sera were double-blind tested by the RFFIT and ELISA. The VNA titer cut-off value of ELISA was set at 1.5 IU/mL to ensure no false-positive. The diagnostic specificity and sensitivity were 100% and 91.1%, respectively. CONCLUSIONS: The validation data characterize this ELISA as a suitable method for semi-quantitative measurement of VNA titers in human serum samples to assess vaccination status. The ELISA kit can offer simplicity, speed, low cost and high throughput, making it a practical tool for monitoring the immune response following vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhao R, Yu P, Shan Y, et al. Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects. Vaccine. 2019. PMID: 31471146. doi:10.1016/j.vaccine.2019.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。